News Sentiment

VRTX sentiment intelligence

Vertex Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 485.65 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend active

+0.1% over one week, +7.5% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?

Market Reaction

Balanced read

55/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 7.5% over four weeks
Fair value 11.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 33
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 18
simplywall.st 6
Simply Wall Street 5
TradingView 2
MarketWatch 2
The Globe and Mail 2
Seeking Alpha 2
TIKR.com 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 12
Deals and strategy 5
Analyst action 3
Regulatory and legal 3
Guidance 2
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
TradingView Direct company coverage

Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating Crinetics Pharmaceuticals (CRNX), Twin Vee PowerCats Co. (VEEE), NextCure, Inc. (NXTC), and TriCo Bancshares (TCBK) for potential violations of federal securities laws and breaches of fiduciary duties related to thei

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 19:11
Source
TradingView
marketscreener.com Direct company coverage

Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19

Morgan Stanley has downgraded Vertex Pharmaceuticals (VRTX) from "Overweight" to "Equalweight" and significantly reduced its price target from $19 to $15. This adjustment reflects a more cautious outlook from the investment bank regarding the pharmaceutical company's future perfo

Tone
Neutral 50/100
Event
Guidance
Published
21 Jul 2026 09:39
Source
marketscreener.com
Simply Wall Street Direct company coverage

Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal Plans

Vertex Pharmaceuticals (VRTX) stock is currently trading below its estimated intrinsic value, according to a Discounted Cash Flow (DCF) model, despite a mixed picture from broader valuation checks and an upcoming $10 billion acquisition of Crinetics Pharmaceuticals. While the DCF

Tone
Neutral 50/100
Event
Deals and strategy
Published
21 Jul 2026 01:09
Source
Simply Wall Street
Market source Direct company coverage

Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today

Vertex Pharmaceuticals (VRTX) shares dropped by 1.06% to $480.50, underperforming the broader S&P 500, Dow, and Nasdaq markets. Despite this daily dip, the drugmaker has seen a 7.53% appreciation over the past month, outperforming its sector and the S&P 500. Investors are now loo

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 21:38
Source
Market source
MarketWatch Direct company coverage

Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors

Shares of Vertex Pharmaceuticals Inc. (VRTX) fell 1.06% on Monday, closing at $480.50. This underperformance occurred during a generally poor trading session where the S&P 500 Index declined by 0.19% and the Dow Jones Industrial Average dropped by 0.59%. This marks the second con

Tone
Negative 26/100
Event
Market update
Published
20 Jul 2026 16:37
Source
MarketWatch
ad-hoc-news.de Direct company coverage

Vertex Pharma stock trades near highs as cystic fibrosis portfolio drives double digit revenue growt

Vertex Pharmaceuticals (Vertex Pharma) stock is trading near highs due to robust revenue and profit growth driven by its cystic fibrosis (CF) portfolio. The company reported double-digit revenue increases and strong operating margins in its latest quarter, primarily from its CF t

Tone
Neutral 50/100
Event
Earnings
Published
20 Jul 2026 14:14
Source
ad-hoc-news.de
BioSpace Direct company coverage

Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals

Vertex Pharmaceuticals' IgA nephropathy drug, povetacicept, is gaining momentum following recent FDA approvals for competing therapies from Novartis (Fabhalta) and Vera Therapeutics (Trutakna). Analysts believe these approvals will help educate the market and create a positive en

Tone
Positive 71/100
Event
Market update
Published
20 Jul 2026 11:31
Source
BioSpace
Simply Wall Street Direct company coverage

Exploring High Growth Tech Stocks In The US For July 2026

This article identifies top-performing high-growth tech stocks in the US for July 2026, amidst a market that has seen a 17% increase over the past year. It highlights companies like Travere Therapeutics, Madrigal Pharmaceuticals, and Cloudflare, detailing their operational focus,

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 10:41
Source
Simply Wall Street
Quartr Direct company coverage

Crinetics Pharmaceuticals (CRNX) Proxy filing Summary

Vertex Pharmaceuticals is set to acquire Crinetics Pharmaceuticals for approximately $10 billion ($8.8 billion net of cash), paying $85 per share in cash. This acquisition will bring PALSONIFY and atumelnant into Vertex's portfolio, with an expected combined peak annual revenue p

Tone
Positive 66/100
Event
Deals and strategy
Published
20 Jul 2026 09:41
Source
Quartr
Market source Direct company coverage

Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2

Vertex Pharmaceuticals' gene therapy, exagamglogene autotemcel (Casgevy), has received expanded FDA approval to treat children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This approval provides new options for a pediatric group with limi

Tone
Positive 75/100
Event
Regulatory and legal
Published
20 Jul 2026 05:07
Source
Market source
The Globe and Mail Direct company coverage

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching

Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion to diversify its portfolio beyond its dominant cystic fibrosis drug market. The acquisition introduces Palsonify for acromegaly and pipeline candidates like atumelnant for congenital adrenal hyperp

Tone
Positive 71/100
Event
Deals and strategy
Published
19 Jul 2026 22:08
Source
The Globe and Mail
Fierce Biotech Direct company coverage

Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax

Latigo Biotherapeutics plans an IPO to fund its non-opioid pain drug pipeline, including late-stage studies for LTG-001, an oral small-molecule Nav1.8 inhibitor. The company aims to compete with Vertex Pharmaceuticals' Journax, highlighting potential advantages in efficacy and ad

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 14:07
Source
Fierce Biotech
Stocktwits Direct company coverage

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?

Penguin Solutions (PENG), Arista Networks (ANET), and Biocryst Pharmaceuticals (BCRX) all reached 52-week highs due to positive market sentiment and various catalysts. PENG benefited from increased analyst price targets driven by AI demand, ANET saw optimism for its cloud network

Tone
Positive 65/100
Event
Analyst action
Published
18 Jul 2026 15:40
Source
Stocktwits
Simply Wall Street Direct company coverage

Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?

Arrowhead Pharmaceuticals (ARWR) has seen recent stock volatility, with a 4.1% gain in the past day but an 8.3% drop over the last month, yet a strong 1-year return. Analysts view the stock as undervalued with a fair value of $89.08 against its current $74.30, driven by its promi

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2026 11:41
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Will Pediatric Casgevy Expansion and Canadian ALYFTREK Talks Change Vertex Pharmaceuticals' (VRTX) Narrative?

U.S. regulators recently expanded approval of Vertex Pharmaceuticals' gene-editing therapy Casgevy for pediatric patients as young as 2 years old. Concurrently, Canada's pan-Canadian Pharmaceutical Alliance has initiated discussions for public reimbursement of Vertex's cystic fib

Tone
Positive 74/100
Event
Regulatory and legal
Published
18 Jul 2026 03:47
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Can Catalyst Pharmaceuticals (CPRX) Keep Looking Fairly Valued Now?

Catalyst Pharmaceuticals stock has seen a significant 4.6x return over the past five years, yet its current valuation appears to be roughly in line with its fundamentals rather than being clearly cheap or overvalued. The company's P/E ratio of 17.4x is close to its estimated fair

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2026 01:39
Source
Simply Wall Street
scanx.trade Direct company coverage

Monteverde investigates Element Solutions, Crinetics, and AstroNova sales

Monteverde & Associates PC is investigating the proposed sale of Element Solutions Inc to Solstice Advanced Materials Inc for potential undervaluation and process adequacy. The firm is also scrutinizing the acquisitions of Crinetics Pharmaceuticals by Vertex Pharmaceuticals and A

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jul 2026 22:40
Source
scanx.trade
MarketWatch Direct company coverage

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains

Shares of Vertex Pharmaceuticals Inc. (VRTX) rose 1.88% on Thursday, closing at $486.03. Despite this gain, the stock underperformed the broader market, with the S&P 500 Index falling 0.51% and the Dow Jones Industrial Average dropping 0.20%. This marks the second consecutive day

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 16:36
Source
MarketWatch